clinical trial · NCT04845399
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
Hemophilia ARecombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
brief summary
The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult patients with hemophilia A.
started
Apr 16, 2021
primary completion
Jun 26, 2021
completion
Jun 26, 2021
last updated
Aug 29, 2023
official title
A Single-Arm, Multicenter, Open-label Phase III Expansion Trial Evaluating Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in Adolescent and Adult Patients With Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol